Not all individuals with CLL involve therapy. In spite of all current advances, the iwCLL nevertheless recommends watchful observation for sufferers with asymptomatic illness.86 This suggestion is predicated on at least two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).